LivaNova (NASDAQ:LIVN) Price Target Raised to $70.00 at Robert W. Baird

LivaNova (NASDAQ:LIVN) had its price target upped by Robert W. Baird from $63.00 to $70.00 in a research note issued to investors on Thursday,Benzinga reports. Robert W. Baird currently has an outperform rating on the stock.

A number of other brokerages have also issued reports on LIVN. The Goldman Sachs Group set a $55.00 target price on LivaNova and gave the company a “neutral” rating in a research report on Wednesday, October 1st. Weiss Ratings restated a “sell (d-)” rating on shares of LivaNova in a report on Wednesday, October 8th. Wall Street Zen raised LivaNova from a “buy” rating to a “strong-buy” rating in a research report on Saturday, August 9th. Barclays raised their price objective on shares of LivaNova from $55.00 to $58.00 and gave the company an “equal weight” rating in a research note on Thursday, August 21st. Finally, Mizuho upped their target price on shares of LivaNova from $65.00 to $70.00 and gave the stock an “outperform” rating in a research note on Thursday. Five investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, LivaNova has a consensus rating of “Moderate Buy” and an average target price of $62.43.

LivaNova Trading Up 0.3%

Shares of NASDAQ LIVN traded up $0.16 during mid-day trading on Thursday, reaching $55.36. 600,033 shares of the company’s stock were exchanged, compared to its average volume of 669,058. The company’s 50-day moving average is $53.76 and its 200-day moving average is $48.73. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.09 and a current ratio of 1.29. The firm has a market capitalization of $3.02 billion, a price-to-earnings ratio of -14.23 and a beta of 1.00. LivaNova has a 52-week low of $32.48 and a 52-week high of $58.91.

LivaNova (NASDAQ:LIVN) last posted its earnings results on Wednesday, November 5th. The company reported $1.11 EPS for the quarter, beating analysts’ consensus estimates of $0.91 by $0.20. LivaNova had a negative net margin of 16.13% and a positive return on equity of 14.57%. The company had revenue of $357.80 million for the quarter, compared to analysts’ expectations of $342.32 million. During the same quarter in the prior year, the company posted $0.90 earnings per share. LivaNova’s revenue for the quarter was up 12.5% compared to the same quarter last year. LivaNova has set its FY 2025 guidance at 3.800-3.90 EPS. Analysts expect that LivaNova will post 2.85 EPS for the current fiscal year.

Institutional Investors Weigh In On LivaNova

Institutional investors and hedge funds have recently bought and sold shares of the stock. Primecap Management Co. CA grew its holdings in shares of LivaNova by 0.7% during the second quarter. Primecap Management Co. CA now owns 4,641,352 shares of the company’s stock worth $208,954,000 after purchasing an additional 32,942 shares during the last quarter. Vanguard Group Inc. raised its stake in LivaNova by 13.5% during the 1st quarter. Vanguard Group Inc. now owns 2,666,880 shares of the company’s stock valued at $104,755,000 after acquiring an additional 316,993 shares during the last quarter. Artisan Partners Limited Partnership lifted its position in LivaNova by 94.5% during the 3rd quarter. Artisan Partners Limited Partnership now owns 2,427,045 shares of the company’s stock worth $127,129,000 after acquiring an additional 1,179,436 shares during the period. Wellington Management Group LLP grew its stake in shares of LivaNova by 83.5% in the 3rd quarter. Wellington Management Group LLP now owns 2,345,516 shares of the company’s stock valued at $122,858,000 after purchasing an additional 1,067,349 shares during the last quarter. Finally, AQR Capital Management LLC lifted its holdings in shares of LivaNova by 30.5% during the second quarter. AQR Capital Management LLC now owns 2,049,820 shares of the company’s stock worth $92,201,000 after purchasing an additional 478,525 shares during the period. 97.64% of the stock is owned by hedge funds and other institutional investors.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.